Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US.
Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Gao Q, Palagashvilli T, Alam S, Mues KE, Bhatt DL, Kosiborod MN; GOULD Investigators. Cannon CP, et al. Among authors: rosenson rs. JAMA Cardiol. 2021 Jun 16;6(9):1-9. doi: 10.1001/jamacardio.2021.1810. Online ahead of print. JAMA Cardiol. 2021. PMID: 34132735 Free PMC article.
Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States.
Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Yazdi D, Elliott-Davey M, Mues KE, Bhatt DL, Kosiborod MN; GOULD Investigators. Cannon CP, et al. Among authors: rosenson rs. Am Heart J. 2020 Jan;219:70-77. doi: 10.1016/j.ahj.2019.10.014. Epub 2019 Oct 31. Am Heart J. 2020. PMID: 31726422 Free article.
Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
Shaik A, Kosiborod M, de Lemos JA, Gao Q, Mues KE, Alam S, Bhatt DL, Cannon CP, Ballantyne CM, Rosenson RS; GOULD Investigators. Shaik A, et al. Among authors: rosenson rs. Clin Cardiol. 2022 Dec;45(12):1303-1310. doi: 10.1002/clc.23923. Epub 2022 Sep 19. Clin Cardiol. 2022. PMID: 36124341 Free PMC article.
The Evolving Future of PCSK9 Inhibitors.
Rosenson RS, Hegele RA, Fazio S, Cannon CP. Rosenson RS, et al. J Am Coll Cardiol. 2018 Jul 17;72(3):314-329. doi: 10.1016/j.jacc.2018.04.054. Epub 2018 Jul 9. J Am Coll Cardiol. 2018. PMID: 30012326 Free article. Review.
Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP, Sanchez RJ, Klimchak AC, Khan I, Sasiela WJ, Reynolds MR, Rosenson RS. Cannon CP, et al. Among authors: rosenson rs. Am J Cardiol. 2019 Apr 15;123(8):1202-1207. doi: 10.1016/j.amjcard.2019.01.028. Epub 2019 Jan 25. Am J Cardiol. 2019. PMID: 30736965 Free article.
Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease.
Arnold SV, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Mues KE, Alam S, Elliott-Davey M, Bhatt DL, Cannon CP, Kosiborod M; GOULD Investigators. Arnold SV, et al. Among authors: rosenson rs. Circulation. 2019 Aug 13;140(7):618-620. doi: 10.1161/CIRCULATIONAHA.119.041730. Epub 2019 Jun 7. Circulation. 2019. PMID: 31174429 No abstract available.
Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease.
Colantonio LD, Hubbard D, Monda KL, Mues KE, Huang L, Dai Y, Jackson EA, Brown TM, Rosenson RS, Woodward M, Muntner P, Farkouh ME. Colantonio LD, et al. Among authors: rosenson rs. J Am Coll Cardiol. 2020 Jul 21;76(3):251-264. doi: 10.1016/j.jacc.2020.05.048. J Am Coll Cardiol. 2020. PMID: 32674789 Free article.
Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, Mancini GB, Ballantyne CM, Catapano A, Gouni-Berthold I, Stein EA, Xue A, Wasserman SM, Scott R, Thompson PD; GAUSS-3 Investigators. Nissen SE, et al. Among authors: rosenson rs. Clin Cardiol. 2016 Mar;39(3):137-44. doi: 10.1002/clc.22518. Epub 2016 Mar 4. Clin Cardiol. 2016. PMID: 26946077 Free PMC article. Clinical Trial.
427 results